Immatics

Immatics Financial Leverage

The Financial Leverage (Equity Multiplier) of Immatics (IMTX) as of Nov 21, 2026 is 1.16. In the previous year, Financial Leverage (Equity Multiplier) was 1.21 — a change of -4.08% (lower).

Financial Leverage

1.16

YoY

-4.08%

Last updated:

Financial Leverage (Equity Multiplier) of Immatics is 2025 1.16 . Financial Leverage (Equity Multiplier) of Immatics was 2024 1.21 . It decreases by -4.08% lower compared to the previous year.

The Immatics Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2019
-3.21 EUR
Jan 1, 2020
2.44 EUR
Jan 1, 2021
7.26 EUR
Jan 1, 2022
1.91 EUR
Jan 1, 2023
2.27 EUR
Jan 1, 2024
1.21 EUR
Jan 1, 2025
1.16 EUR
The Immatics Financial Leverage history
YEARFinancial LeverageYoY
1.16-4.08%
1.21-46.55%
2.27+18.42%
1.91-73.64%
7.26+197.15%
2.44-176.13%
-3.21—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Immatics Stock analysis

What does Immatics do? Immatics NV develops T cell receptor-based immunotherapies for cancer treatment, focusing on solid tumors through Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). The company's pipeline includes eight therapeutic programs, with four in clinical trials: IMA201 (MAGEA4/8), IMA202 (MAGEA1), ACTolog IMA 101 (Multi-target pilot trial), and IMA203 (PRAME). Four programs are in preclinical development, such as IMA204 (COL6A3) and IMA401 (Cancer testis antigen). Immatics generates revenue through licensing agreements and potential future sales of its therapies, targeting pharmaceutical companies and research institutions seeking advanced cancer treatments. The company's clinical-stage therapies are designed to enable robust T-cell responses against cancer targets, with programs like IMA201 and IMA202 focused on solid tumors. IMA203 addresses both hematological and solid cancers, while preclinical programs like IMA401 and IMA402 target cancer testis antigens. Immatics partners with biopharmaceutical firms to advance its pipeline, leveraging its TCR technology platform to develop therapies for unmet medical needs in oncology. Immatics' revenue model relies on strategic partnerships and licensing deals with pharmaceutical companies, which fund clinical development and gain access to its proprietary TCR platform. The firm's focus on solid tumors and hematological cancers attracts interest from major biopharmaceutical players looking to expand their oncology portfolios. Through its eight therapeutic programs, Immatics aims to deliver innovative treatments that address high unmet medical needs in cancer therapy. Immatics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Immatics stock

Financial Leverage (Equity Multiplier) of Immatics is 1.16 in 2025.

Financial Leverage (Equity Multiplier) of Immatics changed from 1.21 to 1.16, representing a -4.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Immatics since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Immatics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Immatics

All Key Metrics — Immatics